research funding database


Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional | substance abuse | worldwide)

Share this post

funding consultation boking
Logo of scientifyRESEARCH + logo of Enago "Author First, Quality First" scientifyRESEARCH recommends English editing and author support services from Enago.

The Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional) funding program from he National Institutes of Health (NIH) supports highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). Applications are open to researchers at research institutions in the USA and worldwide. Applications are also open to small businesses. The award provides 275,000 USD over 2 years (plus indirect costs).

Opportunity number: PAR-21-208

The next letters of intent are due on July 13, 2024. Applications close on August 13, 2024.

Adverts. Premium members do not see Google Ads.

Please Login / Subscribe to our premium membership to see the content. Sign up to Free trial to see detailed funding information.

non member

Sign-up for our monthly
research funding newsletter

you can unsubscribe at any time

Be the first to know

Sign-up for Personalized Grant Alerts